Welcome to our dedicated page for Intellia Therape news (Ticker: NTLA), a resource for investors and traders seeking the latest updates and insights on Intellia Therape stock.
Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a clinical-stage biotechnology leader pioneering CRISPR/Cas9 gene editing therapies. This page serves as the definitive source for official company announcements, including clinical trial updates, regulatory milestones, and strategic partnerships.
Investors and researchers will find curated press releases detailing NTLA's progress in treating genetic disorders like hereditary angioedema and ATTR amyloidosis. Content spans therapeutic pipeline developments, intellectual property advancements, and collaborative research initiatives with industry partners.
All materials are organized to facilitate quick scanning of critical updates while maintaining technical accuracy. Regular updates ensure stakeholders stay informed about NTLA's work in precision gene editing without promotional bias.
Bookmark this page for direct access to Intellia's latest financial reports, scientific publications, and conference participation details. Check back frequently for real-time updates on CRISPR-based therapeutic innovations.
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leader in genome editing, will announce its first quarter 2023 financial results and operational highlights on May 4, 2023, at 8 a.m. ET. Investors can participate via a conference call or a live webcast. The company focuses on developing potentially curative therapeutics using CRISPR-based technologies through its in vivo and ex vivo programs, targeting specific disease-causing genes. Intellia aims to harness the full potential of genome editing for transformative genetic therapies, supported by its robust intellectual property portfolio and clinical development experience.
Intellia Therapeutics (NASDAQ:NTLA) announced the appointment of Bill Chase to its board of directors, effective immediately. Chase will also chair the audit committee, succeeding Caroline Dorsa, who is retiring on June 15, 2023, following her appointment as chair of Biogen's board. Bill Chase has over 30 years of experience in financial management, having served as CFO at AbbVie and held various roles at Abbott. This leadership change is aimed at strengthening Intellia's governance as it advances its CRISPR-based therapies into late-stage clinical development. CEO John Leonard emphasized Chase's financial acumen as a valuable asset in the company's mission to develop novel gene therapies.
Intellia Therapeutics (NASDAQ: NTLA) announced that the U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation for its investigational therapy NTLA-2002, aimed at treating hereditary angioedema (HAE). This CRISPR-based treatment targets the kallikrein B1 (KLKB1) gene to prevent life-threatening swelling attacks. The RMAT designation facilitates accelerated development and review, including early FDA interactions and potential priority review. NTLA-2002 has also received Orphan Drug Designation and Innovation Passport status. Intellia is currently conducting a Phase 1/2 study to evaluate the safety and efficacy of NTLA-2002.
FAQ
What is the current stock price of Intellia Therape (NTLA)?
What is the market cap of Intellia Therape (NTLA)?
